Abstract
The forkhead box O1 (FOXO1) transcription factor plays a key role in wound healing process. Recently it has been reported that lineage-specific genetic ablation of FOXO1 significantly improves diabetic wound healing in a mouse model. To investigate the clinical usefulness of these findings, translational preclinical studies with a large animal model are needed. We report for the first time that the local application of a FOXO1 inhibitor (AS1842856) significantly improves connective tissue healing in a preclinical T2DM minipig model, reflected by increased collagen matrix formation, increased myofibroblast numbers, improved angiogenesis, and a shift in cell populations from pro-inflammatory (IL-1β+, TNF-α+and iNOS+) to pro-healing (CD163+). Our results set up the basis for the clinical application of a FOXO1 antagonist in early diabetic wounds where there is impaired connective tissue healing.
Original language | English (US) |
---|---|
Pages (from-to) | 781-791 |
Number of pages | 11 |
Journal | American Journal of Translational Research |
Volume | 13 |
Issue number | 2 |
State | Published - 2021 |
Keywords
- Diabetes
- Forkhead box O1 (FOXO1)
- Hyperglycemia
- Inflammation skin
- Minipig
- Wound healing
ASJC Scopus subject areas
- Molecular Medicine
- Clinical Biochemistry
- Cancer Research